Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
daNIS-2: NIS793 + Gemcitabine/Nab-paclitaxel in First-Line mPDAC
NCT04935359Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2021
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 27
01
Overview
A Phase 3 trial of nisevokitug in pancreatic adenocarcinoma (PDAC), sponsored by Novartis. Started Sep 2021; status: completed.
02
Drugs
nisevokitug
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04935359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04935359.